Editor's letter

Issue 144 • July 2024

Don’t miss out – sign up to our free industry-leading magazine and newsletters

Cover image: Volodymyr Kryshtal / Getty Images

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

After trialling a subscription-style system for procuring antimicrobial drugs, the UK’s National Health Service recently announced that it will formalise this approach to help spur research in this space. Historically, companies developing antimicrobial drugs have found it difficult to build revenues on these much-needed drugs considering antibiotic stewardship programs. This month’s cover story breaks down how such an approach could help address that.

Also, this month, we take a look at how the Swiss biotech landscape has weathered the tough financial ecosystem of last year, which continues to keep companies from listing on public exchanges.

Included in this issue is the latest coverage on oncology drug development following the American Society of Clinical Oncology 2024 Annual Meeting, and an interview on how patient advocacy is changing clinical research. All this, along with the latest news and deals in the pharmaceutical landscape.

Manasi Vaidya, editor

Go to article: Home | UK’s new Netflix-style funding model for antibiotics goes liveGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: NiproGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Körber Company InsightGo to article: KörberGo to article: In DepthGo to article: UK’s new Netflix-style funding model for antibiotics goes liveGo to article: Swiss biotech ecosystem recuperates from global financial instabilityGo to article: Can supermarket pharmacies plug urgent healthcare gaps?Go to article: Will WHO’s new guidance spur hepatitis B immunisation?Go to article: ASCO24: Moderna/MSD’s cancer vaccine may transform melanoma landscapeGo to article: How patient advocacy can lead to more successful and meaningful clinical trialsGo to article: Sponsored SupplementsGo to article: Lactalis IngredientsGo to article: Avenga Company InsightGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue